Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D'Amico, T. A., DeCamp, M., Dilling, T. J., Dowell, J., Gettinger, S., Grotz, T. E., Gubens, M. A., Hegde, A., Lackner, R. P., Lanuti, M., Lin, J., Loo, B. W., Lovly, C. M., Maldonado, F., Massarelli, E., Morgensztern, D., Ng, T., Otterson, G. A., Pacheco, J. M., Patel, S. P., Riely, G. J., Riess, J., Schild, S. E., Shapiro, T. A., Singh, A. P., Stevenson, J., Tam, A., Tanvetyanon, T., Yanagawa, J., Yang, S. C., Yau, E., Gregory, K., Hughes, M. 2022; 20 (5): 497-530

Abstract

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. Patients with metastatic lung cancer who are eligible for targeted therapies or immunotherapies are now surviving longer. This selection from the NCCN Guidelines for NSCLC focuses on targeted therapies for patients with metastatic NSCLC and actionable mutations.

View details for DOI 10.6004/jnccn.2022.0025

View details for PubMedID 35545176